Document:

EX-10.5

 Exhibit 10.5 

 
  
 FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 
 This First Amendment to Exclusive License Agreement (this “Amendment”), dated as of November 4, 2005, is made by and among The Regents of the University of 

California, a California corporation (“The Regents”), Medivation, Inc ., a Delaware corporation
(“Medivation”), and Medivation Prostate Therapeutics, Inc, a Delaware corporation and subsidiary of Medivation (“MPT”) 
 WHEREAS, The Regents, Medivation and MPT are parties to an Exclusive License Agreement, dated as of August 12, 2005 (the “Exclusive License Agreement”); 

WHEREAS, The Regents, Medivation and MPT wish to strengthen the patent protection of certain members of the family of
compounds covered in UC Case Nos 2004-129 and 2005- 438 by the filing of a patent application to cover additional selected diaiylthiohydantoin compounds, which are disclosed in UC Case No, 2006-260 entitled “Selected Diarylthiohydantoin
Compounds,” by Samedy Ouk, Michael E lung, Derek Welsbie and Charlie D Chen, employees of The Regents, and Charles I Sawyers, an employee of HHMI and a member of the faculty of the University of California, Los Angeles; 

WHEREAS, Medivation as the parent corporation of MPT will benefit directly from the agreements made herein; 

WHEREAS, the parties mutually intend to enter into this First Amendment to amend the terms of the Exclusive license
Agreement, as specified below. 
 THEREFORE, the patties hereby agree as follows: 

	 1
	  
	 Paragraph 1,1 (“Regents’ Patent Rights”) is deleted and replaced with the following,

 which is amended to include “UC Case No. 2006-260” in the parenthetical at
the end of 
 the paragraph: 
 11 “Regents’ Patent Rights” means The Regents interest in the claims of the United States patents and patent applications, corresponding foreign patents and patent
applications (requested under Paragraph 7,3 herein), and any reissues, extensions, substitutions, continuations, divisions, and continuation-in-part applications (but only those claims in the continuation-in-part applications that are entirely
supported in the specification and entitled to the priority date of the parent application) based on the patent applications listed in Appendix A (UC Case Nos 2004-129, 2005-438 and 2006-260). 

 

 
  

	 2
	  
	 Appendix A (Regents’ Patent Rights) is deleted and replaced with the Appendix A

 attached to this First Amendment, which is amended to include the patent application to be
filed under UC Case No 2006-260. 
 3, Paragraph 2 1 is deleted and replaced with the following, which is amended
to delete 
 “Licensee” and replace it with “MPT .” The effect of this Amendment is that MPT
is the sole recipient of the license granted pursuant to Paragraph 2 1 Notwithstanding this amendment, it is expressly understood that all other references to “Licensee” in the Exclusive License Agreement, including without limitation in
Article 18 thereof (Indemnification), shall refer to Medivation and MPT collectively, 

	 2
	  
	 1 Subject to the limitations set forth in this Agreement, including the licenses granted to the United States
Government and those reserved by HHMI set forth in the recitals and in Paragraph 2 2 and the rights reserved by The Regents in Paragraph 2.3, The Regents hereby grants to MPT an exclusive license (the “License”) under Regents’ Patent
Rights, in jurisdictions where Regents’ Patent Rights exist, to make, have made, use, sell, offer for sale and import Licensed Products and to practice Licensed Methods in the Field of Use to the extent permitted by law,

	 4
	  
	 Except for the amendments specifically referenced above, all other terms of the Exclusive

 License Agreement shall remain unchanged and in full force and effect, 

The Regents, Medivation and MPT have executed this Amendment in duplicate originals by their 

authorized officers on the dates written below: 
 MEDIVATION, INC 
 Bv /s/ C. Patrick Machado

 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 

By: /s/ Claire T. Wake, Ph.D. 
 Name C, Patrick Machado 
 Name Claire T Wake, Ph D

 T itle Senior Vice President and CFO 
 Title Assistant Director, licensing 
 Date 4 Nov,
05 Date November 4, 2005 MEDIVATION PROSTATE THERAPEUTICS, INC. f By /s/ C. Patrick Machado Name C, Patrick Machado T itle Senior Vice President and CFO 
 Date 4 Nov. 05 

 

 
  
 APPENDIX A (First Amendment) 

REGENTS* PATENT RIGHTS 
 lIC Case No. 2004-129 
 PCT Patent Application
No,, US05/05529 “Methods and Materials for Assessing Prostate Cancer Iherapies and Compounds,” filed February 23, 2005, based on US Provisional Patent Application No, 60/547,101 filed February 24, 2004, The inventors are Michael
E Jung, Samedy Ouk, Charlie D, Chen and Derek Welsbie, employees of The Regents, and Charles I Sawyer s, an employee of the Howard Hughes Medical Institute (“HHMI”) and a member of the faculty of The Regents 

UC Case No. 2005-438 
 US Provisional Patent Application No, 60/680,835 “Novel Androgen Receptor Inhibitors with Minimal Agonistic Activities,” fried May 11, 2005 The inventors are Michael E.
Jung, Samedy Ouk, Charlie D Chen and Derek Welsbie, employees of The Regents, and Charles L Sawyer s, an employee of the Howar d Hughes Medical Institute (“HHMI”) and a member of the faculty of The Regents This application, together with
the patent application pertaining to UC Case No 2004-129, cover the compounds identified as RD1 through RD138, inclusive, on Exhibit A attached her eto , 
 UC Case No. 2006-260 
 US Provisional Patent
Application to be filed on “Selected Diarylthiohydantoin Compounds” based on UC Case No 2006-260 The inventors are Michael E. Jung, Samedy Ouk, Charlie D, Chen and Derek Welsbie, employees of The Regents, and Charles L Sawyers, an employee
of the Howard Hughes Medical Institute (“HHMI”) and a member of the faculty of The Regents This application will cover only the following diaiylthiohydantoin compounds developed in the labor atory of Michael E Jung, the structures of which
are set forth on Exhibit A attached hereto: 
 ? RD139 through RD142 

? RD145 through RD163 
 ? RD168 

 

 
  
 EXHIBIT A
To Appendix A 
 [begins on Page 5] 

	 2
	  
	 

	 1
	  
	 

 

 
  
  

RD2 
  

RD3 
  

RD4 
  

RD5 
  

RD6 
  

RD7 
  

RD8 

 

 
  
 RD9

  
 RD10 

 
 RD11 

 
 RD12 

 
 RD13 

 
 RD14 

 
 RD15 

 
 RD16 

 
 RD17 

 

 
  
  

RD18 
  

RD19 
  

RD20 
  

RD20 
  

RD22 
  

RD23 
  

RD24 
  

RD25 
 RD18 
  
 RD# 
  
 RD26 
  
 RD1 
  
 RD8 

 

 
  
  

RD28 
  

RD28 
  

RD29 
  

RD30 
  

RD31 
  

RD32 
  

RD33 
  

RD34 
  

RD35 

 

 
  
 RD37

  
 RD38 

 
 RD39 

 
 RD40 

 
 RD41 

 
 RD42 

 
 RD43 

 
 RD44 

 
 RD27 

 
 RD35 

 
 RD35 

 

 
  
  

RD45 
  

RD46 
  

RD47 
  

RD48 
  

RD49 
  

RD50 
  

RD51 
  

RD52 

 

 
  
  

RD53 
  

RD54 
  

RD55 
  

RD57 
  

RD58 
  

RD59 
  

RD60 

 

 
  
 RD61

  
 RD62 

 
 RD63 

 
 RD64 

 
 RD65 

 
 RD66 

 
 RD67 

 
 RD45 

 
 RD53 

 
 RD52 

 
 RD60 

 
 RD36 

 
 RD44 

 

 
  
 RD68

  
 RD69 

 
 RD70 

 
 RD71 

 
 RD72 

 
 RD73 

 
 RD74 

 
 RD75 

 
 RD# 

 
 O 

 
 RD61 

 
 O 

 
 RD67 

 
 RD67 

 

 
  
  

RD78 
  

RD79 
  

RD80 
  

RD81 
  

RD82 
  

RD83 
  

RD84 

 

 
  
 RD85

  
 RD86 

 
 RD87 

 
 RD88 

 
 RD89 

 
 RD90 

 
 RD91 

 
 RD78 

 
 RD78 

 
 RD84 

 
 RD84 

 
 RD68 

 
 RD75 

 

 
  
 RD92

  
 RD93 

 
 RD94 

 
 RD95 

 
 RD85 

 
 RD85 

 
 RD# 

 
 RD91 

 

 
  
  

RD96 
  

RD97 
  

RD98 
  

RD99 
  

RD100 
  

RD101 

 

 
  
 RD102

  
 RD103 

 
 RD104 

 
 RD105 

 
 RD106 

 
 RD107 

 
 RD108 

 
 RD109 

 
 RD96 

 
 RD96 

 
 RD101 

 
 RD101 

 
 RD92 

 

 
  
 RD110

  
 RD111 

 
 RD112 

 
 RD113 

 
 RD114 

 
 RD115 

 
 RD116 

 
 RD# 

 
 RD# 

 
 RD109 

 
 RD109 

 

 
  
 RD117

  
 RD118 

 
 RD119 

 
 RD120 

 
 RD121 

 
 RD122 

 
 RD123 

 
 RD110 

 
 RD110 

 
 RD# 

 
 RD# 

 

 
  
  

RD124 
  

RD125 
  

RD126 
  

RD127 
  

RD128 
  

RD129 
  

RD130 
  

RD131 
  

RD132 

 

 
  
 RD133

  
 RD134 

 
 RD135 

 
 RD136 

 
 RD137 

 
 RD138 

 
 RD139 

 
 RD# 

 
 RD# 

 
 RD132 

 
 RD132 

 
 RD117 

 
 RD123 

 

 
  
 RD140

  
 RD141 

 
 RD142 

 
 RD145 

 
 RD146 

 
 RD92 

 
 RD92 

 

 
  
 RD147

  
 RD148 

 
 RD149 

 
 RD150 

 
 RD151 

 
 RD152 

 
 RD153 

 
 RD154 

 
 RD92 

 
 RD92 

 

 
  
 RD155

  
 RD156 

 
 RD157 

 
 RD158 

 
 RD159 

 
 RD160 

 
 RD161 

 
 RD162 

 
 RD147 

 
 RD147 

 
 RD154 

 
 RD# 

 

 
  
  

RD163 
  

RD164 
 RD# 
  
 RD# 
  
 26 
  
 26 
  
 RD155 
  
 RD162EX-10.6

 Exhibit 10.6 
 

 
  
 SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT UC Agreement Control No. 2006-04-0085 
 This Second Amendment to Exclusive License Agreement (“Second Amendment”), dated as of 
 , 2006, is made by and among The Regents of the University of 
 California, a California corporation (“The Regents”), Medivation, Inc , a Delaware corporation (“Medivation”), and Medivation Prostate Therapeutics, Inc , a Delaware
corporation and subsidiary of Medivation (“MPT”) 
 WHEREAS, The Regents, Medivation and MPT are
parties to an Exclusive License Agreement, dated as of August 12, 2005 (the “Exclusive License Agreement”); 
 WHEREAS, Medivation has been supporting research in Dr Michael E Jung’s laboratory at UCLA under a Sponsored Research Agreement with an Effective Date of August 12, 2005 (the
“Sponsored Research Agreement”); 
 WHEREAS, an invention has been developed at UCLA in the performance
of the Sponsored Research Agreement, which is disclosed in UC Case No 2006-537 entitled “New Jhiohydantoin Androgen Receptor Antagonists for Treatment of Prostate Cancer” by Michael E Tung and Dongwon Yoo, employees of The Regents, Charles
L Sawyers, an employee of Howard Hughes Medical Institute (“HHMI”) and a member of the faculty of the University of California, Los Angeles, and Chris Tran, an employee of HHMI; 

WHERE AS, the Sponsored Research Agreement grants Medivation the first right to negotiate for a license to inventions made
by The Regents in the performance of the Sponsored Research Agreement, and Medivation has exercised its right and wishes to obtain an exclusive license to the invention noted in the preceding WHEREAS clause; 

WHEREAS, Medivation as the parent corporation of MPT will benefit directly from the agreements made her ein; and

 WHEREAS, the parties mutually intend to enter into this Second Amendment to amend the terms of the Exclusive
License Agreement, as specified below 
 THEREFORE, the parties hereby agree as follows: 

	 1
	  
	 Paragraph 1 1 (“Regents’ Patent Rights”) is deleted and replaced with the following, which is
amended to include “UC Case No. 2006-537” in the parenthetical at the end of the paragraph: 

 1.1 “Regents’ Patent Rights” means The Regents interest in the claims of the United States patents and patent applications, corresponding foreign patents and patent
applications (requested under Paragraph 7 3 herein), and any reissues, extensions, substitutions, continuations, divisions, and continuation-in-part applications (but only those claims in the continuation-in-part applications that are entirely
supported in the specification and entitled to the priority date of the parent application) based 
 U.C.
AGREEMENT CONTROL NUMBER 
 2006 04-0085 REVC 

 

 
  
 on the
patent applications listed in Appendix A (UC Case Nos. 2004-129, 2005-438, 2006-260 and 2006-537) 

	 •
	  
	 Appendix A (Regents’ Patent Rights) is deleted and replaced with the Appendix A attached to this First
Amendment, which is amended to include the patent application filed under UC Case No 2006-537 

	 •
	  
	 In consideration for the addition of UC Case No 2006-537 to the Exclusive License Agreement, Medivation will
pay to The Regents a fee of five hundred dollars ($500) within thirty (30) days of the Effective Date of this Second Amendment, 

	 •
	  
	 Except for the amendments specifically referenced above, all other terms of the Exclusive License Agreement
shall remain unchanged and in full force and effect 

 The Regents, Medivation and MPT have
executed this Amendment in duplicate originals by their 
 authorized officers on the dates written below:

					
	 MEDIVATION, INC,.
	  	 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

	 /s/ C. Patrick Machado
	  	 By
	  	 /s/ Claire T. Wake, Ph.D.

	 Name C Patrick Machado
	  	 Name
	  	 Claire T Wake, Ph D

	 Title Senior Vice President and CFO
	  	 Title
	  	 Assistant Director, Licensing

	 Date 8 MAY 06
	  	 Date
	  	 
	 MEDIVATION PROSTATE THERAPEUTICS,
	  	 INC.
	  	 
	 /s/ C. Patrick Machado
	  	 	  	 
	 Name C Patrick Machado
	  	 	  	 
	 Title Senior Vice President and CFO
	  	 	  	 
	 Date CU
	  	 	  	 

 

 
  
 APPENDIX A
(Second Amendment) 
 REGENTS’ PATENT RIGHTS 

UC Case No. 2004-129 
 PCT Patent Application No, US05/05529 “Methods and Materials for Assessing Prostate Cancer Therapies and Compounds filed February 23, 2005, based on US Provisional Patent
Application No,, 60/547,101 filed Februaiy 24, 2004 The inventors are Michael E Jung, Samedy Ouk, Charlie D Chen and Derek Welsbie, employees of The Regents, and Charles L Sawyer s, an employee of the Howar d Hughes Medical Institute
(“HHMI”) and a member of the faculty of The Regents , 
 UC Case No. 2005-438 

US Provisional Patent Application No. 60/680,8.35 “Novel Androgen Receptor Inhibitors with Minimal Agonistic
Activities ,” filed May 13, 2005 The inventors are Michael E Jung, Samedy Ouk, Charlie D. Chen and Derek Welsbie, employees of The Regents, and Charles L Sawyers, an employee of the Howard Hughes Medical Institute (“HHMI”) and a
member of the faculty of The Regents. This application, together with the patent application pertaining to UC Case No 2004-129, cover the compounds identified as RD1 through RD138, inclusive, on Exhibit A attached to the First Amendment 

PCT Patent Application No. PCT/US06/11417 (also includes UC Case Nos. 2006-260 & 2006- 537) titled
“Diarylthiohydantoin Compounds” was filed March 29, 2006 The inventors are Michael E . Jung, Samedy Ouk, Charlie D Chen, Der ek Welsbie and Dongwon Yoo, employees of The Regents, and Charles L Sawyers, an employee of Howard Hughes
Medical Institute (“HHMI”) and a member of the faculty of the University of California, Los Angeles, and John Wongvipat and Chris Tran, employees of HHMI 
 UC Case No. 2006-260 
 US Provisional Patent
Application No. 60/750,351 filed December 15, 2005 and US Provisional 
 Patent Application
No. 60/756,552 filed January 6, 2006, both titled “Selected 
 Diarylthiohydantoin
Compounds,” filed January 6, 2006 (both were subsequently rolled into PCT Patent Application No PCT/US06/11417), The inventors are Michael E Jung, Samedy Ouk and Charlie D Chen, employees of The Regents, and Charles L, Sawyers, an employee
of the Howard Hughes Medical Institute (“HHMI”) and a member of the faculty of The Regents, and John Wongvipat and Chris Tran, employees of HHMI This application will cover only the following diarylthiohydantoin compounds developed in the
laboratory of Michael E Jung, the structures of which are set forth on Exhibit A attached hereto: 

	 •
	  
	 RD139 through RD142 

	 •
	  
	 RD145 through RD163 

 RD168 
 UC Case No. 2006-537 

 

 
  
 Body text;

 Chris Tran, an employee of HHMI. This application coveis the following compounds: RD162’, RD1627’,
RD169 and RD170 (analogues of earlier compounds RD162 and RD131)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}]]